UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035068
Receipt number R000039914
Scientific Title Observational study of the correlation between the geriatric assessment tools and prognosis of the geriatric patients with myelodysplastic syndrome (prospective observational study)
Date of disclosure of the study information 2018/12/15
Last modified on 2018/12/27 16:09:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Observational study of the correlation between the geriatric assessment tools and prognosis of the geriatric patients with
myelodysplastic syndrome (prospective observational study)

Acronym

Observational study of the correlation between the geriatric assessment tools and prognosis of the geriatric patients with
myelodysplastic syndrome (prospective observational study)

Scientific Title

Observational study of the correlation between the geriatric assessment tools and prognosis of the geriatric patients with
myelodysplastic syndrome (prospective observational study)

Scientific Title:Acronym

Observational study of the correlation between the geriatric assessment tools and prognosis of the geriatric patients with
myelodysplastic syndrome (prospective observational study)

Region

Japan


Condition

Condition

myelodysplastic syndrome

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

We confirm whether the geriatric assessment tool can be myelodysplastic syndrome patients prognostic prediction

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

5 years survival rate stratified by geriatric assessment tool

Key secondary outcomes

monthly hospital days stratified by geriatric assessment tool
decrease rate of the score of EQ-5D-5L stratified by geriatric assessment tool
remission rate by treatment intensity stratified by geriatric assessment tool
survival rate by treatment intensity stratified by geriatric assessment tool


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

65 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

65 years of age or older
patients diagnosed with myelodysplastic syndrome
patients who got written informed consent

Key exclusion criteria

patients who treat chemotherapy for hematological malignancy

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Suyama Takuya

Organization

Hitachi general hospital

Division name

hematology,oncology

Zip code


Address

2-1-1 Jonan-cho,Hitachi City,Ibaraki prefecture

TEL

0294231111

Email

sutaku2468@yahoo.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Suyama Takuya

Organization

Hitachi general hospital

Division name

hematology,oncology

Zip code


Address

2-1-1 Jonan-cho,Hitachi City,Ibaraki prefecture

TEL

0294231111

Homepage URL


Email

sutaku2468@yahoo.co.jp


Sponsor or person

Institute

Hitachi general hospital

Institute

Department

Personal name



Funding Source

Organization

Hitachi general hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 12 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2018 Year 11 Month 29 Day

Date of IRB


Anticipated trial start date

2018 Year 12 Month 15 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

observational study
all patients who met the selection criteria in patients who visited our hospital forom December 2018 to December 2026
Items to be measured:age,sex,PS,G8,R-IPSS, Charlson comobidity index,EQ-5D-5L(registration,Half a year, 1 year, 2 year, 3 year, 4 year, 5 year),serum Alb,hospital days,Chemotherapy, treatment effect, presence or absence of relapse, survival date, date of death


Management information

Registered date

2018 Year 11 Month 29 Day

Last modified on

2018 Year 12 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039914


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name